Stereotaxis and Acutus Medical Announce First Integrated Cardiac Ablation Procedure with TeleRobotic Support
July 31 2020 - 08:05AM
Stereotaxis (NYSE: STXS) and Acutus Medical today announced the
first integrated cardiac ablation procedure benefiting from remote
TeleRobotic Support. Dr. Gery Tomassoni of Baptist Health in
Lexington, KY treated the patient utilizing integrated Stereotaxis
Robotic Magnetic Navigation and Acutus AcQMap systems supported by
technical and clinical experts from each company using proprietary
connectivity technology.
The integrated therapeutic approach combines
high-resolution, real-time cardiac imaging and mapping from Acutus'
AcQMap system with the precision and stability of Robotic Magnetic
Navigation. The integration of these advanced technologies enables
physicians to clearly see a patient's arrhythmia pattern and then
reach targets to deliver therapy with accuracy.
The TeleRobotic capabilities on the Stereotaxis
System provide remote support with real-time diagnostics,
preventative troubleshooting, and specialized clinical support
during live procedures without the incremental risk or need of
having additional personnel in the operating suite.
“In the current and ever-evolving healthcare
environment we have to adapt quickly,” says Dr. Tomassoni. “Using
TeleRobotics to collaborate with technology experts at Stereotaxis
and Acutus has allowed me to maintain my attention on delivering
the best therapy to my patients with a network of industry support
available on demand.”
AcQMap uses high-resolution ultrasound imaging
and charge density mapping to create a clear visual display of the
patient's cardiac anatomy and arrhythmia conduction pattern in real
time, informing ablation strategy beyond the pulmonary veins.
Physicians can then use Stereotaxis Robotic Magnetic Navigation to
steer the catheter according to their treatment strategy, allowing
for precise guidance in areas of the heart that can be challenging
to access. Physicians operate in a control room during the
procedure, reducing radiation exposure that can lead to cancer and
other health issues.
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. The core components of Stereotaxis’
systems have received regulatory clearance in the United States,
European Union, Japan, Canada, China, and elsewhere. For more
information, please visit www.stereotaxis.com.
About Acutus MedicalAcutus
Medical is an arrhythmia management company focused on improving
the way cardiac arrhythmias are diagnosed and treated. Acutus is
committed to advancing the field of electrophysiology with a unique
array of products and technologies which will enable more
physicians to treat more patients more efficiently and effectively.
Through internal product development, acquisitions and global
partnerships, Acutus has established a global sales presence
delivering a comprehensive portfolio of highly differentiated
electrophysiology products that provide our customers with a
complete solution for catheter-based treatment of cardiac
arrhythmias. Founded in 2011, Acutus is based in Carlsbad,
California.
This press release includes statements that may
constitute “forward-looking” statements, usually containing the
words “believe,” “estimate,” “project,” “expect” or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the Company's ability to continue to manage expenses
and cash burn rate at sustainable levels, continued acceptance of
the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, competitive
factors, changes resulting from healthcare policy in the United
States, including changes in government reimbursement of
procedures, dependence upon third-party vendors, timing of
regulatory approvals, the impact of the recent coronavirus
(COVID-19) pandemic and our response to it, and other risks
discussed in the Company's periodic and other filings with the
Securities and Exchange Commission. By making these forward-looking
statements, the Company undertakes no obligation to update these
statements for revisions or changes after the date of this release.
There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside
of the Company's control. In addition, these orders and commitments
may be revised, modified, delayed or canceled, either by their
express terms, as a result of negotiations, or by overall project
changes or delays.
|
|
Stereotaxis Contacts:David L. FischelChairman and
Chief Executive Officer Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com |
Acutus Medical:Levitate(260)
408-5383acutus@levitatenow.com |
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2023 to Mar 2024